Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Four Reasons to Buy This Biotechnology Stock

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), a developer and marketer of RNA-based novel drugs to treat a variety of diseases, has been one of the best performing stocks in the biotechnology sector this year. Year-to-date, the stock has gained almost 250%. Despite the strong gains, there are reasons to believe that Isis Pharmaceuticals still has growth potential. There are four reasons that make Isis Pharmaceuticals an attractive proposition.

ISIS Pharmaceuticals, Inc.Innovative technology
Isis is a position in antisense technology. The technology has been designed to alter a gene’s function, silence a mutation, or activate a gene to compensate for an underlying genetic defect. Antisense technology makes it possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analog) that binds to the messenger RNA (mRNA) produced by the gene and effectively turn that gene on or off. With antisense technology, Isis has been able to generate a broad pipeline of first-in-class drugs. One of the biggest advantages of the antisense platform is that it reduces costs and time to discover and develop drugs when compared to traditional small molecule drugs.

Collaboration with Genzyme for Kynamro
Isis’ lead product candidate is Kynamro for the treatment of patients with homozygous familial hypercholesterolemia, or HoHF. The company has partnered with Genzyme, a subsidiary of French drugmaker Sanofi SA (ADR) (NYSE:SNY), to commercialize Kynamro in the U.S. Genzyme is also pursuing marketing approval for the drug in other markets. An extremely rare disease, HoHF occurs in one out of every 1 million people. However, the actual prevalence of the disease might be underestimated. Currently, some 6,000 people worldwide suffer from HoHF.

Currently, there is just one other approved drug for the treatment of HoHF: Juxtapid from Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR). Juxtapid was launched in January this year after the Food and Drug Administration approved the drug in December 2012. The once-daily pill costs about $295,000 a year. This is where Isis’ Kynamro has an edge. Kynamro, which is an injectable treatment, will cost $176,000 a year.

In addition to costs, Isis’ patents offer strong and extensive protection for the drug and the technology. The FDA has already approved the new drug application for Kynamro in January.

Strategic collaboration in neurology
This month, Biogen Idec Inc. (NASDAQ:BIIB) and Isis entered into a strategic collaboration to advance treatment of neurological disorders. Under the terms of the six-year research collaboration agreement, Biogen will have the exclusive rights to use Isis’ antisense technology to develop therapies for neurological disorders.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.